Gene Therapy for Neurological Disease: State of the Art and Opportunities for Next-generation Approaches

被引:23
|
作者
Morris, Gareth [1 ]
Schorge, Stephanie [1 ,2 ]
机构
[1] UCL, Dept Neurosci Physiol & Pharmacol, London, England
[2] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England
关键词
gene therapy; inducible promoters; epilepsy; microRNA; genetic therapy; MESSENGER-RNA; MAMMALIAN-CELLS; OPEN-LABEL; EPILEPSY; EXPRESSION; VECTOR; ANTICONVULSANT; OVEREXPRESSION; PSEUDOURIDINE; THERAPEUTICS;
D O I
10.1016/j.neuroscience.2022.03.010
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gene therapy for rare monogenetic neurological disorders is reaching clinics and offering hope to families affected by these diseases. There is also potential for gene therapy to offer new and effective treatments for common, non-genetic disorders. Treatments for Parkinson's Disease are in clinical trials, and treatments for refractory epilepsies are due to enter first-in-human clinical trials in 2022. Gene therapies for these disorders are based on delivering genes that address the mechanism of the disease, not repairing a mutated gene. Similar 'mechanistic' gene therapies could offer treatments to a wide range of neurological and neuropsychiatric diseases where there is a known mechanism that could be restored using gene therapy. However, the permanent nature of most gene therapies is a serious drawback for translation of gene therapies to a wide-range of diseases because it could present risk of irreversible adverse effects. Several lines of research are aimed at developing gene therapy approaches that allow for the treatment to be turned on and off, including: using proteins activated by exogenous ligands, and promoters turned on by activators. We review these approaches and propose an overall de-risking strategy for gene therapy for common neurological and psychiatric diseases. This approach is based on using a temporary mRNA-based treatment to initially assess efficacy and safety of the planned manipulation, and only following with permanent, virally-delivered treatment if the approach appears safe and effective. (c) 2022 Published by Elsevier Ltd on behalf of IBRO.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 50 条
  • [31] Next-Generation Metagenomics: Methodological Challenges and Opportunities
    Laudadio, Ilaria
    Fulci, Valerio
    Stronati, Laura
    Carissimi, Claudia
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2019, 23 (07) : 327 - 333
  • [32] MICROSCOPY Next-generation microscope boosts opportunities
    Murphy, Justine
    LASER FOCUS WORLD, 2023, 59 (01): : 14 - 16
  • [33] Next-generation influenza vaccines: opportunities and challenges
    Wei, Chih-Jen
    Crank, Michelle C.
    Shiver, John
    Graham, Barney S.
    Mascola, John R.
    Nabel, Gary J.
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (04) : 239 - 252
  • [34] Next-Generation Thermal Insulation Challenges and Opportunities
    Stovall, Therese K.
    Whitaker, Omas E.
    NEXT-GENERATION THERMAL INSULATION CHALLENGES AND OPPORTUNITIES, 2014, 1574 : VII - VII
  • [35] Next-generation protein therapeutics: Challenges and opportunities
    Cochran, Jennifer
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [36] Hyperspectral opportunities with next-generation QSIP arrays
    LeVan, Paul D.
    Beecken, Brian P.
    INFRARED PHYSICS & TECHNOLOGY, 2009, 52 (06) : 361 - 363
  • [37] Next-generation therapies for celiac disease: The gluten-targeted approaches
    Ribeiro, Miguel
    Nunes, Fernando M.
    Rodriguez-Quijano, Marta
    Carrillo, Jose Maria
    Branlard, Gerard
    Igrejas, Gilberto
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 75 : 56 - 71
  • [38] Next-generation diagnostics and disease-gene discovery with the Exomiser
    Smedley, Damian
    Jacobsen, Julius O. B.
    Jaeger, Marten
    Koehler, Sebastian
    Holtgrewe, Manuel
    Schubach, Max
    Siragusa, Enrico
    Zemojtel, Tomasz
    Buske, Orion J.
    Washington, Nicole L.
    Bone, William P.
    Haendel, Melissa A.
    Robinson, Peter N.
    NATURE PROTOCOLS, 2015, 10 (12) : 2004 - 2015
  • [39] Next-generation diagnostics and disease-gene discovery with the Exomiser
    Damian Smedley
    Julius O B Jacobsen
    Marten Jäger
    Sebastian Köhler
    Manuel Holtgrewe
    Max Schubach
    Enrico Siragusa
    Tomasz Zemojtel
    Orion J Buske
    Nicole L Washington
    William P Bone
    Melissa A Haendel
    Peter N Robinson
    Nature Protocols, 2015, 10 : 2004 - 2015
  • [40] NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy
    Cui, Xi-Wei
    Ren, Jie-Yi
    Gu, Yi-Hui
    Li, Qing-Feng
    Wang, Zhi-Chao
    CURRENT GENE THERAPY, 2020, 20 (02) : 100 - 108